Roche signed a deal with Dualitas Therapeutics to use Dualitas’s Dualscreen bispecific discovery engine, aiming to screen more than 300,000 bispecific antibody combinations. The agreement includes an upfront payment and milestones that could bring total value up to $1 billion, alongside tiered royalties tied to outcomes. Dualitas will run the high-throughput search to identify antibody pairs intended to produce synergistic effects when tethered, targeting immunology and inflammation diseases. The structure suggests Roche is seeking earlier differentiation in bispecific selection rather than relying solely on in-house platform outputs. For the immunology pipeline, the deal adds volume and speed to combinatorial discovery, a response to intensifying competition in T-cell engagers, ADCs, and other immune-modulating formats.